Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback